Can COVID-19 impact the natural history of paracoccidioidomycosis? Insights from an atypical chronic form of the mycosis

Carregando...
Imagem de Miniatura
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Autores
SOUZA, Cesar Augusto Tomaz de
MARQUES, Nathan Costa
QUEIROZ, Wladimir
PATZINA, Rosely Antunes
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.65, article ID e57, 6p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Paracoccidioidomycosis (PCM) is a systemic fungal infection caused by Paracoccidioides spp. It can occur as an acute/subacute form (A/SAF), a chronic form (CF) and rarely as a mixed form combining the features of the two aforementioned forms in an immunocompromised patient. Here, we report a 56-year-old male patient with CF-PCM who presented with atypical manifestations, including the development of an initial esophageal ulcer, followed by central nervous system (CNS) lesions and cervical and abdominal lymphatic involvement concomitant with severe SARS-CoV-2 infection. He was HIV-negative and had no other signs of previous immunodeficiency. Biopsy of the ulcer confirmed its mycotic etiology. He was hospitalized for treatment of COVID-19 and required supplemental oxygen in the intensive unit. The patient recovered without the need for invasive ventilatory support. Investigation of the extent of disease during hospitalization revealed severe lymphatic involvement typical of A/SAF, although the patient`s long history of high-risk exposure to PCM, and lung involvement typical of the CF. Esophageal involvement is rare in non-immunosuppressed PCM patients. CNS involvement is also rare. We suggest that the immunological imbalance caused by the severe COVID-19 infection may have contributed to the patient developing atypical severe CF, which resembles the PCM mixed form of immunosuppressed patients. Severe COVID-19 infection is known to impair the cell-mediated immune response, including the antiviral response, through T-lymphopenia, decreased NK cell counts and T-cell exhaustion. We hypothesize that these alterations would also impair antifungal defenses. Our case highlights the potential influence of COVID-19 on the course of PCM. Fortunately, the patient was timely treated for both diseases, evolving favorably.
Palavras-chave
Paracoccidioidomycosis, COVID-19, Atypical clinical form, Esophagus
Referências
  1. Adil MT, 2021, POSTGRAD MED J, V97, P110, DOI 10.1136/postgradmedj-2020-138386
  2. Benard G, 2000, CLIN INFECT DIS, V31, P1032, DOI 10.1086/318146
  3. Benard G, 2008, MYCOPATHOLOGIA, V165, P209, DOI 10.1007/s11046-007-9065-0
  4. Benard G, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofaa624
  5. Castro CC, 1999, 7 ENCONTRO INT PARAC, P116
  6. Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6
  7. de Castro CC, 1999, BRIT J RADIOL, V72, P717, DOI 10.1259/bjr.72.859.10624334
  8. de Castro LF, 2013, J INFECTION, V67, P470, DOI 10.1016/j.jinf.2013.07.019
  9. de Macedo PM, 2023, PLOS NEGLECT TROP D, V17, DOI 10.1371/journal.pntd.0011322
  10. de Macedo PM, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008559
  11. de Macedo PM, 2018, REV SOC BRAS MED TRO, V51, P111, DOI 10.1590/0037-8682-0318-2017
  12. de Oliveira VF, 2023, MYCOSES, V66, P168, DOI 10.1111/myc.13525
  13. Franco M, 1987, Rev Soc Bras Med Trop, V20, P129, DOI 10.1590/S0037-86821987000200012
  14. Machado Filho J, 1960, Hospital (Rio de Janeiro), V58, P99
  15. Mendes RP, 1986, Rev Soc Bras Med Trop, V19, P93
  16. Mendes RP., 1994, Paracoccidioidomycosis, P233, DOI 10.1111/j.1096-0031.2010.00307.x
  17. Mohammed RN, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964-022-00856-w
  18. Oliveira Goldenberg S, 1962, An Paul Med Cir, V83, P113
  19. Pemán J, 2020, REV IBEROAM MICOL, V37, P41, DOI [10.1016/j.raim.2020.07.001, 10.1016/j.riam.2020.07.001]
  20. PERACOLI MTS, 1991, J MED VET MYCOL, V29, P373
  21. Pedroso VSP, 2009, REV SOC BRAS MED TRO, V42, P691, DOI 10.1590/S0037-86822009000600016
  22. Rego AP, 1980, J Bras Med, V38, P40
  23. Rosa M, 2019, AM J NEURORADIOL, V40, P1681, DOI 10.3174/ajnr.A6203
  24. Shikanai-Yasuda MA, 2017, REV SOC BRAS MED TRO, V50, P715, DOI 10.1590/0037-8682-0230-2017
  25. Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
  26. TUDER RM, 1985, MYCOPATHOLOGIA, V92, P179, DOI 10.1007/BF00437631
  27. Yamaga LYI, 2003, EUR J NUCL MED MOL I, V30, P888, DOI 10.1007/s00259-003-1172-7
  28. Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
  29. ZILIOTTO A JR, 1980, Revista do Instituto de Medicina Tropical de Sao Paulo, V22, P261